Merck & Co., Inc.'s Ditching of Aranesp Biosimilar Highlights Follow-on-Biologics Pitfalls

Seeking Alpha -- The developmental and regulatory minefield confronting companies attempting to develop follow-on-biologics (FOBs), or biosimilars, was highlighted again this week with Merck's (MRK) decision to scrap development of MK-2578, its pegylated form of erythropoietin similar to Amgen’s (AMGN) blockbuster anaemia drug Aranesp.

Back to news